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Ritonavir (RTV) is a HIV protease inhibitor and an important component of anti-HIV therapy.  
Hepatotoxicity has been reported in ~10% of patients who receive RTV-containing regimens.  
However, the hepatotoxicity of RTV-containing regimens was significantly enhanced in subjects 
who were pretreated with rifampicin (RIF), a first-line anti-tuberculosis drug.  RIF is also known 
as a ligand of human pregnane X receptor (PXR), a transcription factor that is highly expressed 
in the liver and regulates drug metabolism and many cellular functions.  We hypothesize that 
RIF-mediated PXR activation potentiates RTV hepatotoxicity.  We used a transgenic mouse 
model that expresses human PXR and human CYP3A4 (TgCYP3A4/hPXR).  A CYP3A4 
transgenic mouse model on the Pxr-null background (TgCYP3A4/Pxr-null) was used as the 
control.  We found that pretreatment with RIF sensitized the TgCYP3A4/hPXR mice to RTV 
hepatotoxicity, and this sensitizing effect was abolished in the TgCYP3A4/Pxr-null mice.  
Furthermore, we found that PXR activation increased RTV bioactivation and unfolded protein 
response.  In summary, PXR is a key modulator of RTV induced liver injury. The results from 
this study can be used to guide decisions on safety considerations regarding RTV-containing 
regimens in clinical practice. 
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1.0  INTRODUCTION 
 HIV is a major public health issue.  The introduction of highly active antiretroviral therapy 
(HAART) to HIV treatment has significantly improved the health outcomes of  HIV patients 
Lipsky [1]. However, adverse drug reactions (ADRs) have emerged as an important problem and 
barrier to achieving the goals of HIV therapy [2]. An ADR is any damaging and unwanted effect 
of a drug at its normal dose in humans that results from its use for diagnosis, treatment or 
prophylaxis of a disease [3]. ADRs are relatively common in HIV patients due to side effects of 
the HIV drugs themselves, the presence of opportunistic infections like tuberculosis (TB) that 
need treatment alongside HIV, and the use of non-prescription medications such as herbs and 
dietary supplements together with HIV medications [4, 5]. ADRs have been reported to be the 
cause of non-adherence and discontinuation of HIV medications [6-10]. Hepatotoxicity is a 
common ADR that occurs with different combinations of HAART [11]. Therefore it is important 
to understand the mechanisms of ADRs associated with HIV medications. 
 
TB is the second deadliest infectious disease after HIV accounting for about 1.5 million 
deaths worldwide in 2013. Out of the 1.5 million deaths, 400,000 deaths were attributed to HIV 
co-infection. (http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf?ua=1). 
This makes TB therapy in HIV positive patients of utmost importance. However, therapy is 
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limited by drug-drug interactions between HIV and TB drugs as well as an increased incidence 
of adverse effects due to the overlapping toxicities of HIV/TB drugs. Second paragraph. 
1.1 PROTEASE INHIBITORS (PIS) IN HIV THERAPY 
The HIV PIs have proved effective in treatment naïve as well as treatment experienced patients. 
They have been reported to show an increased threshold to development of resistance, which 
makes them an ideal choice of treatment in patients with adherence problems [12, 13] and those 
that have developed resistance to other classes of HIV drugs such as non-nucleoside reverse 
transcriptase inhibitors [12]. 
Ritonavir (RTV), a first generation PI, is the pillar of PI based regimen because of its ability 
to boost the therapeutic concentration, decrease dosing frequency and reduce the amount 
required for other PIs by inhibiting their CYP3A4 mediated metabolism [14]. Nonetheless, the 
use of PIs has been limited by an increased risk of side effects and drug-drug interactions with 
drugs like RIF used for the treatment of TB and herbal drugs like the St John’s wort used for the 
treatment of depression [15-17]. 
RTV has been reported to be associated with an increased risk of liver injury and 
gastrointestinal side effects that has led to the discontinuation of therapy by patients [18]. In a 
study conducted in HIV patients on PI regimens in Italy, RTV treatment accounted for about 
36% of treatment discontinuation after one year of therapy [6]. Further analysis identified RTV 
to account for the highest number of ADRs in HIV patients on PI-based treatment [6].  Another 
study in Uganda on HIV patients switched to second line RTV/lopinavir based regiment, there 
was a good virological response after 36 months of therapy but about 62% of patients 
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experienced at least one adverse effect. These study showed PI based regimens to be effective 
but limited by toxicities [19].  
 
RTV metabolism has been studied in both humans and animals. The CYP3A4 is the 
principal enzyme responsible for RTV metabolism and to a lesser extent CYP2B6 [20, 21]. 
Major excretion route is hepatobiliary and about 30% of the drug is excreted in the feces of 
humans unchanged [22]. Studies have shown RTV to be a CYP3A4 mechanism based inhibitor. 
It is believed that RTV is metabolized by CYP3A4 to generate metabolites that bind and inhibit 
CYP3A4 activity thus suggesting the existence of RTV bioactivation pathways [23-25]. Our 
recent study profiled the bioactivation pathways of RTV and discovered 13 new metabolites, five 
of which were particularly interesting because of their chemical reactivity and propensity to react 
with glutathione [26]. Four of these five bioactivation pathways were found to be CYP3A 
dependent [26]. Results from this study further support the fact that RTV is a CYP3A substrate 
and undergoes bioactivation.  
 
1.2 RIFAMPICIN (RIF) AND PREGNANE X RECEPTOR (PXR) 
RIF is one of the first line drugs for TB treatment and belongs to the family of the rifamycins. It 
kills the mycobacteria TB by inhibiting the DNA dependent RNA polymerase thus terminating 
protein transcription [27]. RIF is a potent CYP3A4 enzyme inducer because of its ability to 
activate the PXR [28]. A significant number of the pharmacokinetic drug-drug interactions in 
HIV/TB therapy are mediated by RIF, because of its enzyme inducing effect. For example, RIF 
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was reported to reduce the therapeutic plasma concentration of indinavir and saquinavir both 
HIV protease inhibitors by about 92% and 80% respectively [15]. Therefore, RIF has been 
employed as a tool drug for studying PXR activation because of its potent ligand effect [29]. 
 
The PXR is a ligand dependent nuclear transcription factor that activates its target genes by 
forming a heterodimer with retinoid X receptor (RXR), which binds to the PXR DNA response 
element of target genes to induce their transcription [29]. It is highly expressed in the liver and 
small intestine [28-31].   
The PXR regulates the expression of phase I enzymes like CYP3A4, CYP2B6, CYP2C9 and 
CYP24 [29, 32-35]; phase II enzymes namely glutathione S-transferase (GST), sulfotranferase 
2A1 (SULT2A1), UDP-glucoronosyl transferase 1A1(UGT1A1) [36-40]; as well as transporters 
such as multidrug resistance protein (MDR1), multidrug resistance associated protein 2 (MRP2), 
and organic anion transporting polypeptide 2 (OATP2) [41-43]. Aside the regulation of drug 
metabolism, PXR also plays important physiological roles in glucose and lipid metabolism, 
inflammation, bile acid and bone homeostasis [36, 44-48]. 
A wide variety of PXR ligands exist from prescription drugs to herbal medicines, dietary 
food compounds, environmental chemicals/contaminants as well as endogenous compounds like 
steroid hormones and some essential vitamins [31, 49, 50]. The antibiotics RIF and clotrimazole 
are potent ligands of the human PXR [29]. The herbal medicine St John’s wort was reported to 
be a more potent ligand than RIF [51]. Lignans such as enterolactone found in foods such as rye, 
berries and whole grains are low to moderate PXR ligands [52]. Organochlorine pesticides 
chlordane, dieldrin and endosulfan have also been reported to be PXR ligands [49]. Progestogens 
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like 5β Pregnan-3, 20-dione and estrogens like 17β estradiol are weak activators of the PXR [29, 
52]. Dihydroxyvitamin D3, vitamin E and vitamin K are also PXR ligands [36, 50, 52]. 
 
Owing to the existence of huge number of PXR ligands and its effect on drug metabolizing 
enzymes and transporters, the PXR has been implicated in ADRs and pharmacokinetic drug-drug 
interactions in the clinic. Acetaminophen (APAP) a widely used over the counter analgesic 
causes liver injury with an overdose [53]. Induction of drug metabolizing enzymes especially 
CYP2E1 has been shown to enhance the conversion of APAP to the toxic metabolite N-acetyl-p-
benzoquinone imine (NAPQI) that interacts with cellular macromolecules in the liver to cause 
injury [54-56]. However, activation of the PXR and induction of CYP3A4 by RIF was found to 
increase APAP induced liver injury in TgCYP3A4/hPXR mice co-treated with RIF and APAP 
compared to either treatment alone and their wild type, hPXR and Pxr-null counterparts [57]. 
Likewise, the human PXR was shown to modulate liver injury caused by RIF and isoniazid co-
therapy through perturbation of the heme synthesis pathway, which causes the accumulation of 
the hepatotoxin protoporphrin IX [58]. 
 
Since the discovery of the Pxr in mouse, further research has revealed its activation to be 
specie specific [29, 31]. The PXR has a conserved DNA binding domain having an amino acid 
sequence similarity of >94% with other PXR orthologs in mice, rats, rabbits and rhesus monkey 
[59-61]. However, It was reported that the amino acids in the ligand-binding domain of the 
human PXR differs significantly from that of other species. For example, it shares a sequence 
similarity of only 77% with mice, which may account for the differences in its response to 
xenobiotic across species [61, 62]. In line with this example, pregnonelone 16α-carbonitrile 
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(PCN) is a potent mouse Pxr activator but a weak human PXR activator. Similarly, RIF is a 
strong human PXR activator but not a potent mouse Pxr ligand. Due to this specie differences, 
the PXR- humanized mouse model was generated to bridge the gap in studying the human PXR 
in vivo [61]. 
1.3 DRUG-INDUCED LIVER INJURY IN RIF AND RTV CONTAINING THERAPY 
Reports from various pharmacokinetic trials optimizing doses of RTV boosted PIs when 
administered alongside potent enzyme inducers like RIF have shown an alarming rate of drug-
induced liver injury in volunteers. In a study by Schmitt et al, volunteers who received RIF for 
two weeks before starting saquinavir/RTV (SQV/RTV-1000/100mg) presented with much severe 
adverse effects compared to those who started with SQV/RTV followed by RIF. The study had 
to be discontinued because all study participants had developed some level of hepatitis >2times 
the upper limit of normal [63]. Similar adverse effects were observed in HIV patients treated 
with a super boosted lopinavir /RTV (LPV/RTV-400/400mg) [64]. Despite these observations, 
the mechanism underlying liver injury during RIF pretreatment followed by an RTV containing 
regimen is not clearly understood. One may speculate that RIF pretreatment increases the 
expression of CYP3A4, which increases the bioactivation of RTV, possibly increasing the 
generation of reactive metabolites that can elicit liver injury. Therefore there is a need to 
understand the mechanisms behind RTV induced liver injury so that strategies can be designed to 
ameliorate or prevent such events in HIV patients exposed to PXR ligands. 
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1.4 SPECIFIC AIMS OF THE RESEARCH 
The overall goal of this study was to investigate the mechanisms behind drug-induced liver 
injury during pretreatment with RIF followed by RTV regimen. The specific aims of the research 
were: 
1. To determine if ligand activation of the human PXR modulates RTV induced liver injury. 
This was achieved by comparing TgCYP3A4/hPXR mice with the TgCYP3A4/Pxr-null mice 
pretreated with RIF followed by RTV.  
2. To understand the processes that lead to liver injury associated with RIF pretreatment 
followed by RTV. This was accomplished by investigating the involvement of oxidative stress 
and endoplasmic reticulum (ER) stress in mediating RTV induced liver injury.   
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2.0  MATERIALS AND METHODS 
2.1 ANIMAL MODELS  
TgCYP3A4/hPXR and TgCYP3A4/Pxr-null mice were requested from Dr Frank 
Gonzalez lab in NIH. Animals were genotyped by polymerase chain reaction (PCR). Briefly, 
about 0.5 cm of tail was clipped from mice at the time of weaning and placed into a 1.5 ml 
eppendorf tube. About 500 μL of lysis buffer containing proteinase K was placed into the tube 
and incubated on a shaker at 37°C overnight. Next day, samples were centrifuged at 14,000 g for 
10 min and supernatant was used for DNA extraction. DNA pellet obtained was air dried and re-
suspended in 100 μL of distilled water.  
The PCR reaction mix 25 μL containing 3 μL (100 ng) of DNA, 2.5 μL 10x PCR buffer 
minus Mg (Invitrogen, Carlsbad, CA), 0.5 μL 10 mM dNTPs (Invitrogen, Carlsbad, CA), 0.75 
μL 50 mM MgCl2 (Invitrogen, Carlsbad, CA), and 0.125 μL iTaq DNA polymerase (Invitrogen, 
Carlsbad, CA) was heated for 5 min at 94°C, and then cycled 34 (29 for TgCYP3A4) times at 
94°C for 30 sec (95°C for TgCYP3A4), 58°C for 30 sec (60°C for TgCYP3A4), 72°C for 45 sec 
and 72°C for 10 min (5 min for TgCYP3A4), then 37°C for 5 min (TgCYP3A4 only).The 
following primers were used to identify the mouse PXR WT and null alleles: PXR-Fwd1, 5’-
CTGGTCATCACTGTTGCTGTACCA-3’; PXR-Rev2, 5’ 
GCAGCATAGGACAAGTTATTCTAGAG-3’; and PXR-Rev3, 5’ 
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CTAAAGCGCATGCTCCAGACTGC-3’ amplifying a PCR product of 348 bp for WT allele 
and 265 bp for Pxr-null allele [65]. Primers used for the human CYP3A4 transgene were: 
CYP3A4-Fwd2, 5’-TGG AAT GAG GAC AGC CAT AGA GAC-3’; CYP3A4-REV2 5’-AGA 
AGA GGA GCC TGG ACA GTT ACT C-3’ amplifying a PCR product of 521 bp. 
2.2 EXPERIMENTAL DESIGN  
All male mice (two months old) were kept under a 12 h dark and 12 h light cycle with 
water and food ad libitum. Mice were fed with control diet and RIF 100 mg/kg diet for 6 days. 
RTV 25 mg/kg dissolved in 1% DMSO and corn oil was administered on the seventh day and 
continued for 5 more days. Handling was in accordance with University of Pittsburgh study 
protocols. Animals were sacrificed by cervical dislocation on the twelfth day. Blood and liver 
samples were collected and snap frozen and stored at -80°C till use.  
2.3 MICROSOME PREPARATION AND WESTERN BLOT ANALYSIS 
Liver tissue was homogenized in ice-cold buffer (containing 0.1 M phosphate buffer pH 
7.5, sucrose 0.25 M and KCl 0.154 M). Microsomes were prepared by centrifuging liver 
homogenate at 12,100 rpm for 25 min at 4°C. The resulting supernatant was centrifuged at 
37,100 rpm for 1h at 4°C. Microsomal pellets were re-suspended in same buffer used for 
homogenization. Protein quantification was carried out using the BCA method. For western blot 
analysis, 1µg protein from each sample was separated by SDS-polyacrylamide gel 
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electrophoresis, electrophoretically transferred to nitrocellulose membranes (Schleicher & 
Schuell, Keene, NH), and probed using anti-mouse ubiquitin antibody (Santa Cruz). Goat anti-
rabbit was used as secondary antibody. Immunoreactive proteins were detected by 
chemiluminescence blot detection kit (Thermo Scientific). 
2.4 BIOCHEMICAL ASSAYS 
Alanine amino transferase (ALT) and alkaline phosphatase (ALP) assays were carried out 
using serum. Briefly, serum was obtained by centrifuging blood samples collected in heparinized 
tubes at 10,000 g for 10 min at room temperature. Ten μL of serum samples was incubated with 
200 μL of reagent mixture made according to the standard kit procedure (Pointe Scientific, INC). 
Absorbance was read using a spectrophotometer (Bio Rad) at 37°C and wavelength of 340 nm 
and 405 nm for ALT and ALP respectively. 
2.5 RNA ANALYSIS 
RNA was extracted from liver tissues using TRIzol reagent (Ambion, life technologies). 
Quantitative PCR (qPCR) was done using cDNA generated from 0.5 ug total RNA using the 
Invitrogen kit. qPCR reactions were carried out using the sybr green reagent in Quant studio 
7600 (Applied Biosystems). qPCR values were quantified using the comparative cycle threshold 
(Ct) method and samples were normalized to cyclophilin D. 
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2.6 TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE DUTP NICK END 
LABELING (TUNEL) ASSAY 
Liver slices about 5 mm thick were obtained from TgCYP3A4/hPXR and 
TgCYP3A4/Pxr-null mice and placed in tissue cassettes. The liver tissues were fixed in 
formaldehyde overnight. Tissue blocks were then dehydrated in varying concentrations of 
ethanol (70%, 95% and 100%) at one-hour intervals and then embedded in paraffin overnight. 
Blocks were then placed in xylene to remove fat and alcohol. The tissue was then infiltrated with 
paraffin by placing it in a beaker of melted paraffin overnight. Tissues were then removed from 
the cassettes and embedded in paraffin with the help of a mold.  
The paraffin embedded tissue section was cut to a 4-5 um section. The section was 
deparafinized in an oven at 65°C for 30 min. Then xylene and various concentrations of alcohol 
were used to hydrate tissue sections. Sections were rinsed with PBS and excess water was 
removed using paper towels. Proteinase digestion was carried out by incubating slides with 20 
µg/ml of proteinase K in TE buffer for 15 min at 21-37 °C. The TUNEL mixture was added to 
the sections according to the manufacturer’s instructions. Slides were wrapped carefully in 
parafilm and incubated in a plastic chamber at 37°C for 1 h. Slides were then rinsed three times 
with PBS, mounted with DAPI and covered with glass slips and viewed under a fluorescent 
microscope. 
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2.7 METABOLOMICS 
One hundred mg of liver was weighed from each sample and transferred to a small 12 x 
75mm glass tube. About 500 μL of water (five times weight of liver) was added to each sample. 
Tissue was homogenized on ice using a tissue homogenizer (Thermo Scientific). One hundred 
μL of liver homogenate was transferred to an eppendorf tube and 100 μL of methanol was added 
and vortexed for 30 sec. The resulting mixture was centrifuged at 15,000 rpm for 10 min at room 
temperature. One hundred μL of supernatant was transferred to a new eppendorf tube and 100 μL 
of acetonitrile was added and vortexed well. Mixture was centrifuged again as described above 
and 100 μL of supernatant was transferred to UPLC sample vial for analysis on a qTOFMS. 
2.8  STATISTICAL ANALYSIS 
All tests were carried out using the student t-test comparing the treatment groups between the 
two genotypes. Significant P-values were set as <0.05. 
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3.0  RESULTS/DISCUSSION 
3.1 GENOTYPING 
We used the mouse models expressing human PXR and CYP3A4 to overcome the specie 
differences in the activation of PXR in mice and humans. A TgCYP3A4 on a Pxr-null 
background was used as the control to determine PXR dependent functions (Figure 1A). 
CYP3A4 was significantly induced by RIF treatment in the TgCYP3A4/hPXR but not by 
Pregnonelone-16α-carbonitrile (PCN), a mouse Pxr activator (Figure 1B). 
 
 
 
Figure 1. Mouse models 
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A) PCR genotyping results for TgCYP3A4/hPXR and TgCYP3A4/Pxr-null B) Regulation of 
CYP3A4 in TgCYP3A4/hPXR. Mice were treated with vehicle, RIF or PCN for 3 days. Liver 
microsomes were prepared and analyzed by Western blot. Human liver microsome (HLM) was 
used as the positive control. GAPDH was used as the loading control. 
3.2 ACTIVATION OF HUMAN PXR MODULATES RTV-INDUCED LIVER 
INJURY 
ALT activity has been reported to be a sensitive marker of liver injury [66]. In our study, 
there was a 7-fold increase in ALT activity in the transgenic mice expressing the human PXR 
pretreated with RIF followed by RTV compared to their Pxr-null counterparts (Figure 2A). 
Within the TgCYP3A4/hPXR mice group, there was approximately a 6-fold increase in ALT 
activity in RIF and RTV treatment group compared to vehicle control and treatment of either 
drug alone (Figure 2A). This indicates that liver injury is human PXR dependent and requires 
administration of both RIF and RTV. To further investigate if liver injury truly occurred, 
TUNEL assay, which is a technique used to detect nicked DNA in cells undergoing cell death, 
was carried out. There was a 6-fold increase in dead cells in transgenic mice expressing the 
hPXR compared to their Pxr-null controls further confirming liver injury (Figure 2B-D). ALP 
activity on the other hand showed no significant change between the treatment and control 
groups (data not shown) in both genotypes thus suggesting liver injury to be hepatocellular [67]. 
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Figure 2 Human PXR modulates liver injury associated with RIF pretreatment followed by RTV 
TgCYP3A4/hPXR and TgCYP3A4/Pxr-null mice were pretreated with vehicle (Cont) or RIF for 
6 days. On day 7, RTV (25 mg/kg) was added and continued until day 11. On day 12, all mice 
were sacrificed and blood samples were collected for evaluation of liver injury. (A) Serum 
alanine aminotransferase (ALT) activity. The data are expressed as mean ± SD (n=3-5). *P<0.05 
compared with control. ALT activity was set as 1 in the control group. (B-D) TUNEL assays in 
livers of TgCYP3A4/Pxr-null (B) and TgCYP3A4/hPXR (C) mice pretreated with RIF followed 
by RTV (200X). (D) Relative quantification of TUNEL positive cells. *P<0.05 compared with 
TgCYP3A4/Pxr-null mice (set as 1). 
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3.3 ENDOPLASMIC RETICULUM (ER) STRESS IN RTV-INDUCED LIVER 
INJURY 
The ER is the domain in the cell where protein synthesis, folding and transport to other 
organelles like the golgi apparatus occurs. However, these processes can be disrupted by various 
physiological or noxious stimuli that lead to ER stress [68, 69]. Since, the ER is the focal 
organelle for drug biotransformation, toxic insults from the parent drug or metabolite or both 
may cause perturbation of ER functions leading to ER cellular stress [70]. The cell activates the 
ER stress response pathways to stop further protein synthesis, increase protein-folding capacity 
as well as inhibit the accumulation of misfolded proteins to promote cell survival. However, 
when the ER functions are severely damaged, the cells are targeted toward cell death [69]. 
 
In our studies, electron microscopy of ER revealed dilation and blebbing of the ER in the 
transgenic mice expressing the hPXR pretreated with RIF followed by RTV compared to their 
Pxr-null counterparts (Figure 3A and 3B). This provides evidence that the integrity of the ER is 
affected by RTV-induced liver injury. Furthermore, western blot analysis also revealed the 
accumulation of ubiquinated proteins in the liver of TgCYP3A4/hPXR mice pretreated with RIF 
followed by RTV (Figure 3C). This data is in agreement with a previous study on RTV showing 
proteasome inhibition as a possible mechanism of RTV-induced ER stress though we saw more 
accumulation of the bulk polyubiquinated protein [71]. This may be due to activation of hPXR 
by RIF, which leads to the increased transcription of proteins, but reactive metabolites of RTV 
target the ER proteins, which lead to the misfolding and accumulation of misfolded proteins or 
perturbation of proteasomal protein degradation. 
C/EBP homologous protein (CHOP) is a transcription factor that is induced by ER stress 
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or some other hostile conditions in the cells. It is the main mediator of apoptotic cell death during 
ER stress [69]. We observed a 11-fold increase of CHOP in the TgCYP3A4/hPXR mice 
pretreated with RIF followed by RTV compared to their Pxr-null counterparts and individual 
drug treatment (Figure 3D). These data suggest that RIF pretreatment followed by RTV can 
induce ER stress. Based on our results, we propose that the ER stress is activated during RTV-
induced liver injury. Since the ER stress cellular pathway has three major arms- IRE1-alpha, 
PERK and ATF-6 pathways [72], more studies will be carried out to determine which arm is 
particularly important in mediating RTV-induced liver injury. 
 
 
Figure 3: ER damage, accumulation of ubiquinated proteins and ER stress in the liver of 
TgCYP3A4/hPXR mice pretreated with RIF followed by RTV 
(A and B) Liver images analyzed by transmission electron microscopy in TgCYP3A4/Pxr-null 
(A) and TgCYP3A4/hPXR (B) mice pretreated with RIF followed by RTV. The bubbles (B) are 
dilated ER. (C) Western blot analysis of ubiquitinated proteins in the liver of TgCYP3A4/hPXR 
mice. (D) CHOP expression in the liver. CHOP expression was quantified by qPCR. All data are 
expressed as mean ± SD (n=3-5). *P<0.05 compared with control. 
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3.4 RIF PRETREATMENT FOLLOWED BY RTV THERAPY INDUCED 
OXIDATIVE STRESS IN LIVER OF TGCYP3A4/HPXR MICE 
Metabolomics has been used as an adept approach to study endobiotic homeostasis. The 
chemical profile of liver from TgCYP3A4/hPXR mice pretreated with RIF followed by RTV 
was significantly different from that of vehicle, RIF or RTV treatment groups (Figure 4A). 
Further analysis identified two ions GSSG and ophthalmic acid that are associated with oxidative 
stress. GSSG the oxidized form of glutathione (GSH) is a biomarker of oxidative stress [73] and 
was significantly increased in the liver of TgCYP3A4/hPXR (Figure 4B). Furthermore, 
ophthalmic acid, a GSH analog and sensitive indicator of oxidative stress [74] was also increased 
significantly (Figure 4B and 4C). These findings reveal considerable oxidative stress in the liver 
of TgCYP3A4/hPXR mice pretreated with RIF followed by RTV. 
 
 PXR activation has been reported to enhance oxidative stress as seen in transgenic mice 
with constitutively active PXR (VP-hPXR) showing increased sensitivity to paraquat toxicity, 
and treatment with mouse Pxr agonist, PCN, increased paraquat toxicity in wild type mice [75]. 
Moreover, increased sensitivity was accompanied by a down regulation of superoxide dismutase 
(SOD) and catalase, two enzymes important for the detoxification of reactive oxygen species 
from the body [75]. Thus activation of PXR by RIF in our studies may also enhance oxidative 
stress in addition to CYP3A4 induction that increases generation of RTV reactive metabolites. 
Further studies will be carried out to determine the role of superoxide dismutase (SOD) and 
catalase, in RTV-induced oxidative stress. 
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Figure 4 Metabolomic analysis of liver in TgCYP3A4/hPXR mice pretreated with RIF followed by 
RTV 
(A) Group separation in an OPLS-DA score plot. The t [1] P and t[2]O values represent the score 
of each sample in principal component 1 and 2, respectively. (B) Loading S-plots generated by 
metabolomic analysis in mouse liver. The x-axis is a measure of the relative abundance of ions, 
and the y-axis is a measure of the correlation of each ion to the model. Two top ranking ions are 
labeled in S-plots, which are glutathione disulfide (GSSG) and ophthalmic acid (OA). (C) 
Relative quantifications of OA. All data are expressed as mean ± SD (n=4-7). *P<0.05 compared 
with control. The data in the control group was set as 1. 
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4.0  CONCLUSION 
By using the PXR-humanized mouse model, we demonstrated that PXR potentiates RTV-
induced liver injury (Figure 5). The presence of liver injury in our studies is consistent with 
findings from the clinical studies that reported drug induced liver injury in subjects pretreated 
with RIF followed by an RTV containing regimen [63, 64, 76].  Furthermore, we found that ER 
stress and oxidative stress contribute to liver injury associated with RTV. The results from this 
study can be used to guide clinical decisions on the use of PXR ligands before initiating RTV 
based therapy in patients. Further studies will be carried to provide a deeper insight into the 
mechanisms involved and pathways that can be targeted to ameliorate or prevent RTV induced 
liver injury. 
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Figure 5: Project summary 
RIF and other PXR ligands activate the hPXR, which induces CYP3A4 induction, thus 
exacerbating CYP3A4-mediated RTV bioactivation that potentiates oxidative stress and ER 
stress, leading to liver injury.  
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